These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31584146)

  • 1. Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis.
    Alhadab AA; Rhein J; Tugume L; Musubire A; Williams DA; Abassi M; Nicol MR; Meya DB; Boulware DR; Brundage RC;
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):565-576. PubMed ID: 31584146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania.
    Katende A; Mbwanji G; Faini D; Nyuri A; Kalinjuma AV; Mnzava D; Hullsiek KH; Rhein J; Weisser M; Meya DB; Boulware DR; Letang E;
    Mycoses; 2019 Dec; 62(12):1127-1132. PubMed ID: 31461550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial.
    Rhein J; Huppler Hullsiek K; Tugume L; Nuwagira E; Mpoza E; Evans EE; Kiggundu R; Pastick KA; Ssebambulidde K; Akampurira A; Williams DA; Bangdiwala AS; Abassi M; Musubire AK; Nicol MR; Muzoora C; Meya DB; Boulware DR;
    Lancet Infect Dis; 2019 Aug; 19(8):843-851. PubMed ID: 31345462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.
    Rhein J; Morawski BM; Hullsiek KH; Nabeta HW; Kiggundu R; Tugume L; Musubire A; Akampurira A; Smith KD; Alhadab A; Williams DA; Abassi M; Bahr NC; Velamakanni SS; Fisher J; Nielsen K; Meya DB; Boulware DR;
    Lancet Infect Dis; 2016 Jul; 16(7):809-818. PubMed ID: 26971081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of the antifungal effect of sertraline in the treatment of cryptococcal meningitis in HIV patients: a single Mexican center experience.
    Villanueva-Lozano H; Treviño-Rangel RJ; González GM; Hernández-Rodríguez PA; Camacho-Ortiz A; Castillo-Reyna L; Galindo-Alvarado SG; Martínez-Reséndez MF
    Infection; 2018 Feb; 46(1):25-30. PubMed ID: 28815430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis.
    Stott KE; Beardsley J; Kolamunnage-Dona R; Castelazo AS; Kibengo FM; Mai NTH; Tùng NLN; Cuc NTK; Day J; Hope W
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.
    Sloan D; Dlamini S; Paul N; Dedicoat M
    Cochrane Database Syst Rev; 2008 Oct; (4):CD005647. PubMed ID: 18843697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with early mycological clearance in HIV-associated cryptococcal meningitis.
    Concha-Velasco F; González-Lagos E; Seas C; Bustamante B
    PLoS One; 2017; 12(3):e0174459. PubMed ID: 28355252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis.
    Bisson GP; Molefi M; Bellamy S; Thakur R; Steenhoff A; Tamuhla N; Rantleru T; Tsimako I; Gluckman S; Ravimohan S; Weissman D; Tebas P
    Clin Infect Dis; 2013 Apr; 56(8):1165-73. PubMed ID: 23362285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.
    Longley N; Muzoora C; Taseera K; Mwesigye J; Rwebembera J; Chakera A; Wall E; Andia I; Jaffar S; Harrison TS
    Clin Infect Dis; 2008 Dec; 47(12):1556-61. PubMed ID: 18990067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.
    Hope W; Stone NRH; Johnson A; McEntee L; Farrington N; Santoro-Castelazo A; Liu X; Lucaci A; Hughes M; Oliver JD; Giamberardino C; Mfinanga S; Harrison TS; Perfect JR; Bicanic T
    mBio; 2019 Dec; 10(6):. PubMed ID: 31796539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment for HIV-associated cryptococcal meningitis.
    Tenforde MW; Shapiro AE; Rouse B; Jarvis JN; Li T; Eshun-Wilson I; Ford N
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD005647. PubMed ID: 30045416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of genomic and pharmacokinetic data to predict clinical outcomes in HIV-associated cryptococcal meningitis.
    Stott KE; Mohabir JT; Bowers K; Tenor JL; Toffaletti DL; Unsworth J; Jimenez-Valverde A; Ahmadu A; Moyo M; Gondwe E; Chimang'anga W; Chasweka M; Lawrence DS; Jarvis JN; Harrison T; Hope W; Lalloo DG; Mwandumba HC; Perfect JR; Cuomo CA;
    mBio; 2024 Oct; 15(10):e0159224. PubMed ID: 39189739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial.
    Lawrence DS; Youssouf N; Molloy SF; Alanio A; Alufandika M; Boulware DR; Boyer-Chammard T; Chen T; Dromer F; Hlupeni A; Hope W; Hosseinipour MC; Kanyama C; Lortholary O; Loyse A; Meya DB; Mosepele M; Muzoora C; Mwandumba HC; Ndhlovu CE; Niessen L; Schutz C; Stott KE; Wang D; Lalloo DG; Meintjes G; Jaffar S; Harrison TS; Jarvis JN
    Trials; 2018 Nov; 19(1):649. PubMed ID: 30470259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetic Model and Meta-analysis of Outcomes of Amphotericin B Deoxycholate Use in Adults with Cryptococcal Meningitis.
    Stott KE; Beardsley J; Whalley S; Kibengo FM; Mai NTH; Tùng NLN; Cuc NTK; Kolamunnage-Dona R; Hope W; Day J
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29735567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of fluconazole for cryptococcal meningoencephalitis: implications for antifungal therapy and in vitro susceptibility breakpoints.
    Sudan A; Livermore J; Howard SJ; Al-Nakeeb Z; Sharp A; Goodwin J; Gregson L; Warn PA; Felton TW; Perfect JR; Harrison TS; Hope WW
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2793-800. PubMed ID: 23571544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluconazole plus flucytosine is a good alternative therapy for non-HIV and non-transplant-associated cryptococcal meningitis: A retrospective cohort study.
    Li Z; Liu Y; Chong Y; Li X; Jie Y; Zheng X; Yan Y
    Mycoses; 2019 Aug; 62(8):686-691. PubMed ID: 31120606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis.
    Loyse A; Wilson D; Meintjes G; Jarvis JN; Bicanic T; Bishop L; Rebe K; Williams A; Jaffar S; Bekker LG; Wood R; Harrison TS
    Clin Infect Dis; 2012 Jan; 54(1):121-8. PubMed ID: 22052885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis.
    Eshun-Wilson I; Okwen MP; Richardson M; Bicanic T
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009012. PubMed ID: 30039850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.
    Brouwer AE; Rajanuwong A; Chierakul W; Griffin GE; Larsen RA; White NJ; Harrison TS
    Lancet; 2004 May; 363(9423):1764-7. PubMed ID: 15172774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.